IMCR Earnings & Financial Statements
Immunocore Holdings plc
$28.34
+$0.52(+1.87%)
29
Overall
60
Value
--
Tech
28
Quality
Market Cap
$1.46B
Volume
414.30K
52W Range
$27.56 - $40.71
Target Price
$60.50
IMCR earnings and financial statements: Immunocore Holdings plc's income statement, balance sheet and cash flow statement, annual and quarterly.
IMCR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2024 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | $93.88M | $242.08M | $80.25M | $70.50M | $199.91M |
| Cost of revenue | $831.0K | $2.50M | $448.0K | $246.0K | $835.0K |
| Operating income | -$3.62M | -$55.12M | -$8.50M | -$26.49M | -$55.02M |
| EBITDA | $9.96M | -$18.34M | $10.38M | -$14.64M | -$35.38M |
| Net income | $5.02M | -$55.42M | $8.74M | -$19.24M | -$53.01M |
| EPS (diluted) | $0.10 | $-1.11 | $0.17 | $-0.49 | $-0.84 |
| Fiscal year | 2025 | 2024 | 2024 | 2024 | 2023 |
|---|---|---|---|---|---|
| Total assets | $1.03B | $797.32M | $1.08B | $993.99M | $472.08M |
| Total liabilities | $649.53M | $471.84M | $706.81M | $634.45M | $179.68M |
| Shareholders’ equity | $378.48M | $325.48M | $377.83M | $359.53M | $292.40M |
| Cash and equivalents | $476.85M | $363.26M | $537.77M | $832.82M | $347.67M |
| Long-term debt | $432.28M | $298.38M | $431.76M | $471.53M | $66.06M |
| Fiscal year | 2025 | 2024 | 2024 | 2024 | 2023 |
|---|---|---|---|---|---|
| Operating cash flow | $435.0K | $5.88M | $40.01M | -$4.59M | -$2.00M |
| Free cash flow | $137.0K | $1.93M | $38.42M | -$5.02M | -$7.23M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMCR | $28.34 | +1.9% | 414.30K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |